Lipase Levels and Coronavirus Disease 2019

October 26, 2022 updated by: Cevdet Duran, Uşak University

Association Between Pancreatic Lipase Levels and Coronavirus Disease 2019

Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common.

In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury and acute pancreatitis in the course of COVID 19 disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

4000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Usak, Turkey, 64200
        • Cevdet Duran

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Eighteen years of age or older, whose lipase level is measured in the course of COVID 19, will be included in the study.

Description

Inclusion Criteria:

  • Patients with lipase levels measured during COVID-19

Exclusion Criteria:

Patients with age <18 years Patients with pregnancy Patients whose lipase levels were not measured in the course of COVID-19 Patients with known solid organ malignacy Patients with known hematologic malignacy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients with higher lipase level
patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
Other: Age, gender, hospitalization and mortality rates will be compared
Age, gender, hospitalization and mortality rates will be compared
Control
patients with normal lipase levels in the course of SARS-CoV-2 infection
Other: Age, gender, hospitalization and mortality rates will be compared
Age, gender, hospitalization and mortality rates will be compared

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The frequency of lipase enzyme elevation will be compared
Time Frame: From 31th March 2020 until 9th July 2021
From 31th March 2020 until 9th July 2021
The mortaliy rate will be compared
Time Frame: From 31th March 2020 until 9th July 2021
From 31th March 2020 until 9th July 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uşak University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 31, 2020

Primary Completion (Actual)

July 9, 2021

Study Completion (Actual)

July 9, 2021

Study Registration Dates

First Submitted

October 26, 2022

First Submitted That Met QC Criteria

October 26, 2022

First Posted (Actual)

November 1, 2022

Study Record Updates

Last Update Posted (Actual)

November 1, 2022

Last Update Submitted That Met QC Criteria

October 26, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UsakUCevdet3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatitis

Clinical Trials on Age, gender, hospitalization and mortality rates will be compared

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe